Pharmacokinetics and clinical efficacy of moxalactam in biliary tract infections.
Moxalactam exhibited excellent in vitro activity against all pathogens commonly associated with biliary tract infections. The drug retained bactericidal activity against all of these organisms, with the possible exception of Klebsiella pneumoniae, even in the presence of bile. Pharmacokinetic studies revealed high concentrations of moxalactam in the bile after intravenous administration. Twenty-seven of 28 patients with severe, complicated biliary tract infections responded favorably to the administration of moxalactam.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D001660:Biliary Tract Diseases / Q000188:drug therapy*; D002511:Cephalosporins / Q000627:therapeutic use*; D002513:Cephamycins / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009070:Moxalactam; D013997:Time Factors
D002511:Cephalosporins; D002513:Cephamycins; D009070:Moxalactam